Vumerity 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0014/G 
This was an application for a group of variations. 
03/01/2024 
SmPC 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.a.1 - Stability of FP - Reduction of the shelf 
life of the finished product - As packaged for sale 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IB/0012/G 
This was an application for a group of variations. 
15/12/2023 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
PSUSA/10143
Periodic Safety Update EU Single assessment - 
30/11/2023 
n/a 
PRAC Recommendation - maintenance 
/202303 
dimethyl fumarate, diroximel fumarate (multiple 
sclerosis) 
IB/0013 
B.II.b.3.z - Change in the manufacturing process of 
23/10/2023 
n/a 
the finished or intermediate product - Other variation 
IB/0011/G 
This was an application for a group of variations. 
25/08/2023 
SmPC 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0009 
A.5.b - Administrative change - Change in the name 
20/02/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008/G 
This was an application for a group of variations. 
06/02/2023 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IAIN/0007/G 
This was an application for a group of variations. 
07/11/2022 
03/03/2023 
Annex II and 
PL 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0006 
B.II.b.5.z - Change to in-process tests or limits 
03/11/2022 
n/a 
applied during the manufacture of the finished 
product - Other variation 
II/0005 
Submission of the final report from study ALK8700-
27/10/2022 
n/a 
A301, A Phase 3 Open Label Study to Evaluate the 
Long-term Safety and Tolerability of ALKS 8700 in 
Adults with Relapsing Remitting Multiple Sclerosis 
listed as a category 3 study in the RMP. This is a 
multicentre, open-label study to evaluate the long-
term safety, tolerability, and treatment effect over 
time of DRF administered for up to 96 weeks in adult 
participants with RRMS. 
The RMP version 1.2 has been agreed. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0004 
B.I.a.4.z - Change to in-process tests or limits 
13/06/2022 
n/a 
applied during the manufacture of the AS - Other 
variation 
IB/0003/G 
This was an application for a group of variations. 
02/05/2022 
n/a 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0002/G 
This was an application for a group of variations. 
30/03/2022 
03/03/2023 
SmPC, Annex 
II, Labelling 
and PL 
C.z - To update section 4.8 of the SmPC and section 
4 of the PL, to add the adverse reaction 'Alopecia' 
with a frequency 'Common'. 
C.z - To update section 4.4, 4.8 and 5.1 of the 
SmPC, in order to update the text with regards to 
the lymphocyte recovery. 
C.z - Safety, Efficacy, Pharmacovigilance changes - 
Other variation 
C.z - Safety, Efficacy, Pharmacovigilance changes - 
Other variation 
IA/0001/G 
This was an application for a group of variations. 
10/01/2022 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 6/6 
 
 
 
 
 
 
 
